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Abstract
Background—Our medical center laboratory recently adapted its 24/7, two-hourly testing 
program to use an ARCHITECT-Multispot-viral load (AR-MS-VL) algorithm in place of a 
previous rapid test-immunofluorescence (RT-IF) algorithm.
Objectives—We evaluated screening test performance, acute case detection, turnaround time and 
ability to resolve HIV status under the new algorithm.
Study Design—We considered consecutive HIV tests from January-November 2015. AR-MS-
VL results at Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) were 
compared with RT-IF results at ZSFG and also with AR-MS-VL results in the recently completed 
CDC Screening Targeted Populations to Interrupt On-going Chains of HIV Transmission with 
Enhanced Partner Notification (STOP) Study for targeted testing of MSM at publicly funded 
testing sites in San Francisco.
Results—Among 21,985 HIV tests performed at ZSFG, 16,467 were tested by RT-IF and 5,518 
by AR-MS-VL. There were 321 HIV infections detected, of which 274 (84%) were known HIV+ 
cases, and 47 were newly identified HIV infections (prevalence 0.22%). Under the AR-MS-VL 
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algorithm, turnaround times for screening and full algorithm results were 3 and 21 hours; status-
unresolved cases were reduced (from 47% to 22%) compared with the RT-IF algorithm. The 
positive predictive value (PPV) of a new-positive AR screening test was low (0.44) at ZSFG, 
where no acute infections were detected. At STOP Study sites where acute infection was more 
common, the AR PPV was higher (0.93). All 24 false-positive AR screening tests at ZSFG had a 
signal/cutoff (S/CO) ratio of <15 and all 88 true-positive tests had S/CO ratio >15. Of 62 acute 
infections in the STOP Study, 23 (37%) had an S/CO<15.
Discussion—An AR-MS-VL algorithm is feasible and can return rapid results in a large medical 
center. In this setting, reactive 4th generation assay tests that are negative for HIV antibodies are 
typically false-positive with low S/CO ratios.
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Background
A decade since The Centers for Disease Control (CDC) issued recommendations to expand 
HIV testing as part of routine medical care, US hospitals and medical centers continue to 
develop procedures to scale-up HIV testing [1,2]. Recent policy changes and laboratory 
advances have produced a new HIV testing algorithm [3]. The algorithm was designed to 
improve screening for acute HIV infections, minimize turnaround time, and reduce the 
number of tested patients with unresolved infection status. However, little is known about 
how the algorithm might affect care delivery in a US major medical center with high 
demand for HIV testing.
HIV testing in medical settings involves challenges and considerations that are distinct from 
testing in other settings. There are unique opportunities to test patients who visit the 
emergency department or urgent care but might not otherwise seek testing [4-7], and 
hospital-wide routine HIV screening has been shown to be a valuable tool for identifying 
new infections and preventing missed opportunities to diagnose individuals of unknown 
status [8,9]. These testing opportunities can be driven by symptoms, which may indicate 
acute HIV infection [10] or by the patient care situation (e.g., pregnancy) [11,12]. In caring 
for patients who are sick, ready for discharge, or in labor, there can be a premium on rapid 
turnaround time. Additionally, clinicians use HIV testing to document HIV status in medical 
settings, even when patients report they have already been diagnosed with HIV infection. 
Because hospital labs combine all these disparate modes of clinical testing, it can be 
particularly difficult to study clinical test performance in the medical center laboratory.
The Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) is a major 
provider of emergency/trauma, inpatient, and primary and specialty outpatient care. It is the 
largest provider of ambulatory/drop-in care, indigent care, and primary HIV care in the city. 
In the past decade, ZSFG has mounted an aggressive expansion of HIV testing; integration 
of expanded HIV testing with care has been facilitated by a central laboratory-based, 24/7, 
2-hourly batched testing model innovated at ZSFG allowing high throughput with the 
expectation of rapid (2-3 hour) turnaround [4]. A key component of this expanded HIV 
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testing program is involvement of a dedicated, multidisciplinary clinical team (the Positive 
Health Access to Services and Treatment, or PHAST team) who assist clinicians with 
interpretation of results, track outcomes of confirmatory testing, assist with disclosure of 
positive results [4], facilitate initiation of immediate antiretroviral treatment [13], and 
provide linkage to HIV primary care.
Based on new testing recommendations from the CDC [3], the central laboratory at ZSFG 
switched their standard HIV testing algorithm from their existing rapid testing algorithm 
(Uni-Gold Recombigen® HIV Rapid Test (Trinity Biotech, Co. Wicklow, Ireland(RT)) for 
screening followed by immunofluorescence (IF) confirmation) to a new algorithm with an 
HIV antigen/antibody combo screening test (ARCHITECT® HIV Ag/AB Combo, Abbot 
Laboratories, Abbot Park, IL (AR)) and a HIV-1/2 Ab differentiation assay for confirmation 
(Multispot HIV-1/HIV-2 Rapid Test, Bio-Rad Laboratories, Redmond, WA (MS)); a nucleic 
acid or RNA test is recommended as needed for resolution of discrepant results (Abbott 
RealTime HIV-1 assay, Abbott Molecular Inc., Des Plaines, IL (VL)). (Note: The viral load 
test available at ZSFG (Abbott RealTime HIV-1 assay) is not validated for HIV diagnosis, 
and results are appended with a comment explaining this. Clinicians may use the viral load 
results, along with the AR and MS results, as a supplemental test to guide their patient care, 
and may continue to follow-up with additional diagnostic testing for confirmation.) The 
switch from “RT-IF” to “AR-MS-VL” algorithm took place in September, 2015, and the 
frequency of confirmatory testing also increased from three times per week (IF) to six times 
per week (MS) at this time. Screening tests were performed on batched specimens every two 
hours under both algorithms, with STAT testing available only for specimens from labor and 
delivery. A similar AR-MS-VL algorithm was used and results reported by the Screening 
Targeted Populations to Interrupt On-Going Chains of HIV Transmission with Enhanced 
Partner Notification (STOP) Study at HIV testing venues in New York City, New York, 
North Carolina, and San Francisco, California [14, 15].
For this study, we capitalized on the unique infrastructure at ZSFG for high-throughput 
clinical testing (at the Clinical Laboratory) and for timely and comprehensive follow-up of 
individual cases (by the PHAST team) to prospectively evaluate the impact of the new HIV 
testing algorithm on delivery of HIV testing services in a large, well-resourced, US medical 
center laboratory.
Methods
Objectives
The aim of this study was to determine the real-world performance of the new HIV-testing 
algorithm (AR-MS-VL) in a medical setting. Components of the algorithm evaluated were 
detection of acute infections, turn-around time from sample collection to preliminary and 
final results, ability of the algorithm to resolve HIV status, and performance of the screening 
assay. The study was designed to evaluate algorithm performance using clinical samples in 
the laboratory. The laboratory at ZSFG receives and tests many specimens from individuals 
who are already known to be HIV-positive. Therefore, in order to understand the impact of 
the algorithm on clinical care and testing program performance, we specifically investigated 
its testing performance among patients of unknown HIV status.
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Study Design
This clinical laboratory performance evaluation used cross-sectional data from electronic 
medical records, laboratory administrative data, and PHAST program data from ZSFG 
Hospital and associated medical clinics whose HIV testing was performed in the ZSFG 
central laboratory. We reviewed all consecutive HIV tests at ZSFG from January to 
November 2015, before and after rollout of the new algorithm. Acute infection in the prior 
algorithm was defined as RT-positive with IF-negative or IF-indeterminate results for 
individuals with confirmed HIV infection on subsequent tests. In the new algorithm, acute 
infection was defined as an AR-reactive with MS-negative or MS-indeterminate results for 
individuals with a detectable viral load. Prior HIV testing status was defined based on test 
results in the electronic medical record (EMR) data and detailed chart review for every HIV-
positive test result. Prior status was assigned as unknown for all first tests with negative 
results. For analyses grouping testers by prior status, repeat tests by patients with any 
positive or indeterminate test result were considered as belonging to previously HIV-positive 
testers. Final HIV infection status was defined by the algorithm result and any follow-up 
testing. For patients who screened RT-positive with the prior RT-IF algorithm, algorithm 
resolution was defined as either an IF-positive (true positive) or IF-negative result (false 
positive). IF-indeterminate results were sent out to the San Francisco Department of Public 
Health (SFDPH) for additional testing not yet available at ZSFG (ARCHITECT® HIV 
Ag/AB Combo, Multispot HIV-1/HIV-2 Rapid Test, and VL validated for diagnosis), and 
were considered unresolved by the algorithm, even if final infection status was subsequently 
determined. For patients who screened AR-reactive with the new AR-MS-VL algorithm, 
algorithm resolution was defined as either an MS-positive result (true positive), or an MS-
positive with a VL-detected (acute HIV) or VL-undetected result (false-positive). Time to 
result was measured from the point at which the laboratory received the specimen. AR-
reactive tests were repeated for confirmation before results were reported, and the repeat 
testing was included in turn-around-time calculations. Primary analyses compared the ZSFG 
results obtained using the new testing algorithm (AR-MS-VL: September – November, 
2015) with 1) the ZSFG results obtained using the prior algorithm (RT-IF: January – August, 
2015) and 2) results obtained with the new algorithm (AR-MS-VL) from the CDC STOP 
Study at San Francisco Department of Public Health (SFDPH) targeted testing sites for men 
who have sex with men (MSM) (2010-2013) [14, 15]. For the purpose of this second 
comparison, we excluded previous positive individuals from the ZSFG data in order to be 
consistent with the STOP Study population, where individuals known to be HIV-positive 
were excluded from the study. We also investigated the possible use of a suggested signal-to-
cutoff (S/CO) ratio of 15 in distinguishing between likely true-positive and likely false-
positive results [16] on the screening ARCHITECT assay, in both ZSFG and STOP Study 
populations.
In order to explore the utilization of HIV testing in evaluating patients for acute HIV 
infection on the hospital campus, we collected additional laboratory information on patients 
tested for group A streptococcus, influenza, or infectious mononucleosis testing as indicators 
of having viral syndrome-like illness. The algorithm results and HIV status were determined 
separately for those who were tested for one of these viral-syndrome-like illnesses during 
the study period.
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The study protocol for the clinical laboratory performance evaluation was approved by the 
UCSF Committee on Human Subjects Research (UCSF CHR 12-10141). HIV test result 
data from the STOP Study were not personally identifiable and therefore did not constitute 
research with human subjects.
Results
21,985 HIV tests were performed at ZSFG during the study period, 16,467 using the RT-IF 
antibody algorithm and 5,518 using the AR-MS-VL algorithm (Table 1). A total of 321 HIV 
infections were identified by various clinics and hospital wards, for an overall HIV 
prevalence of 1.5%. However, 274 (85.4%) of the HIV infections identified during this study 
period were among individuals who had a previous HIV-positive test result. Considering 
only the 21,690 testers who were presumed HIV-negative or unknown status at testing, there 
were 47 newly confirmed HIV infections (0.22% prevalence). No antibody-negative or 
antibody-indeterminate acute HIV infections were identified by either algorithm during the 
study period.
Turn-around time using different algorithms
Using the new algorithm, median time to an HIV-negative and HIV-positive screening result, 
respectively, increased from 1.88 (IQR: 1.35, 2.45) and 1.98 hours (IQR: 1.37, 2.65) using 
the Uni-Gold RT to 2.15 (IQR: 1.62, 2.78) and 3.4 hours (IQR: 2.86, 3.98) with the 
ARCHITECT. Under the new algorithm MS testing was considered simpler, faster, and less 
labor intensive than the previous IF which required microscope set-up, processing, and extra 
laboratory space, and the ZSFG lab increased the frequency of confirmatory testing from 
three days per week to six days per week. As a result, the median time from initial test to a 
positive confirmatory result decreased from 41 hours (IQR: 20, 57) for IF to 20 hours (IQR: 
18, 23) for MS (Table 2). In cases where further testing was required after the confirmatory 
result, median time from initial screening test to final resolution was 323 hours (IQR: 264, 
405) after indeterminate IF, and 65 hours (IQR: 49, 115) to a VL test result after a discrepant 
AR-reactive/MS-negative result. Overall, for all patients with a reactive screening test the 
median time to completion of the new algorithm (AR-MS-VL) was substantially shorter than 
time to completion of the prior algorithm (RT-IF) (21 vs. 44 hours).
Resolution of HIV status among patients with negative or unknown HIV status at testing
Of the 21,690 patients with negative or unknown status, there were 85 reactive Uni-Gold RT 
results and 27 reactive ARCHITECT screening results during the study period (Table 2). Of 
the 85 RT reactive tests, 35 (41%) were IF-reactive, 10 (12%) were IF-nonreactive, and 40 
(47%) were IF-indeterminate, requiring additional send-out testing for resolution. By 
contrast, there were no indeterminate MS confirmatory results for any of the 27 positive 
screening tests with the new algorithm (Figure 1a). Sixteen (59.3%) patients had a negative 
MS confirmatory result and, therefore, required VL testing for confirmation under the new 
algorithm. However, status remained unresolved for six (22%) at completion of the testing 
encounter because a sample for viral load testing had not been obtained. Four of those 
patients received follow-up at a later date and were confirmed to be HIV-negative. Two 
patients did not receive follow-up and their final status was not resolved. Overall, the 
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proportion of cases unresolved at the completion of the testing algorithm was reduced from 
47% (40/85) to 22% (6/27) after the implementation of AR-MS-VL testing (Table 2).
Diagnostic performance of screening assays at ZSFG
Interpreting a new reactive screening result is a major challenge in medical settings. Under 
the observational study design we were able to assess the positive predictive value and 
specificity of initial screening test results under RT-IF and AR-MS-VL algorithms, 
considering previously HIV-negative or unknown status testers as the clinically relevant 
population. Under the older RT-IF algorithm, 36 out of 85 RT-reactive screening results were 
confirmed as HIV infected, for a positive predictive value (PPV) of 0.44 (95%CI: 0.33,0.55) 
(Table 2). Under the new algorithm, 11 out of 27 AR-reactive screening results confirmed as 
HIV infected for a similar PPV of 0.44 (95%CI: 0.25, 0.65). The proportion of false-positive 
screening results was similar for RT and AR (54.12% vs. 51.85%). The specificity of both 
assays was high (99.7%), suggesting the low prevalence of disease rather than assay failure 
as the main reason for the low PPV (Table 2).
(Note: The apparent positive predictive values of a reactive RT and AR result appeared 
better when patients who had a previous HIV+ test result were not excluded: RT PPV was 
0.81 (95%CI: 0.75, 0.85) and AR PPV was 0.78 (95%CI: 0.69, 0.85). Thus, from the 
laboratory perspective rather than the testing program perspective, the proportion of true 
positive results would seem much better.)
Comparison of the AR-MS-VL algorithm at ZSFG and STOP Study sites
The positive predictive value of AR-positive screening results was substantially better in the 
local risk-based STOP Study population of unknown-status testers compared to the ZSFG 
population of unknown-status testers (PPV=0.93 vs. 0.44). Sixty three (13.8%) of 455 
initially reactive results in the STOP Study were antibody-negative (AR-reactive/MS-
negative/VL-detected) or antibody-indeterminate (AR-reactive/MS-indeterminate/VL-
detected) acute infections, and the PPV for AR-reactive/MS-negative results was 0.62. No 
acute infections were identified at ZSFG during the study period. Specificity in the STOP 
Study was 99.86%, compared to 99.7% at ZSFG.
ARCHITECT S/CO values
In the ZSFG population, the S/CO value of 15 seemed clearly to separate false from true-
positive results: PPV of a reactive ARCHITECT with S/CO result<15 for HIV infection was 
0/24 (0.00; 95%CI: 0.00, 0.17), while for results with S/CO>15 PPV was 88/88 (1.00; 
95%CI: 0.95,1.00) (Figure 2). In the high risk STOP Study population, however, there were 
many acute HIV infections in which lower values could still connote true infection. Of 62 
acute infections in the STOP Study, 23 (37%) had an S/CO<15. Of 357 non-acute infections, 
20 (5.6%) had an S/CO<15. In this higher-risk population, the PPV of an S/CO<15 was 0.60 
(0.47,0.71), as compared to the PPV for an S/CO value >15 (0.99; 95% CI: 0.98, 1.00).
HIV testing of patients with symptoms of acute viral illness
We were surprised by the low proportion of acute HIV infections in our testing population 
and examined HIV testing and test outcomes among 2762 individuals tested for infectious 
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mononucleosis, group A streptococcus, or influenza at ZSFG during the study period. Of 
those patients, only 277 (10%) had an HIV screening test (AR or RT) done within one day, 
among whom one (0.4%) was a new case and seven (2.5%) were previous positive cases. 
However, among those not tested at the time of this viral illness and who had an unknown 
HIV status, 201 had an HIV test done at a later date during the study period: one (0.5%) was 
a new case and one was unresolved and had a previously negative HIV test. Of the 277 
patients who had an HIV test on the same day they were tested for acute viral illness, 136 
(4.9%) included either AR or VL testing capable of detecting acute infection.
Discussion
In this implementation study, we found that it was feasible to incorporate a recommended 
algorithm, including 4th generation HIV Ag/Ab combo screening and supplemental HIV 1/2 
antibody differentiation, into routine practice in a high throughput hospital laboratory in 
which clinicians expected 2-3 hour turnaround for initial screening results. However, 
switching from a manually performed rapid test to an automated 4th generation assay did not 
reduce the rate of false-positive screening test results or increase the detection of acute HIV. 
Indeed, the positive predictive value (PPV) of a newly positive 4th generation screening test 
result was unexpectedly low compared with data from the CDC STOP Study also conducted 
in San Francisco (PPV 44% vs. 93%). The higher prevalence of acute HIV in the STOP 
Study (13.8% vs. 0) as well as the similarity in assay specificity between the two 
populations suggests that the differences in positive predictive values were related to the low 
prevalence of undiagnosed disease in the ZSFG medical setting rather than test 
characteristics.
Overall, the new algorithm functioned relatively well with regard to the goals of reducing 
overall turnaround time, and resolving more cases without the need for a reference lab. 
Using the combination of HIV 1/2 differentiation antibody testing and viral load, the need 
for send-out testing to resolve the final infection status was reduced dramatically compared 
with the previous immunofluorescence-based approach to confirmation that produced many 
indeterminate results and required follow-up testing at the SFDPH, which often had 
prolonged turn-around-times of several weeks . However, the ability to resolve status by the 
new algorithm was hindered in this initial experience by the inability in some clinical 
circumstances to obtain a sample for viral load testing, which required a separate blood 
draw. The turnaround for viral load confirmation also remained about three days, owing to 
the need for batch viral load testing. These observations point out the potentially important 
role of rapid viral load diagnostic assays in improving HIV testing in medical settings in the 
developed world and the shortcomings of current HIV RNA assays in serving this need. 
They also highlight the benefit of being able to use the same type of specimen for viral load 
testing required for potential confirmation of the HIV screening test. This could enable 
reflex testing on the original specimen without the complication of obtaining a second 
sample from patients who do not stay or fail to return.
One of the key issues raised by the new algorithm is the ability to diagnose acute HIV 
infections, which one might expect to be especially important in medical settings. We found 
that the relative prevalence of acute infection was much lower in this hospital study than it 
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was in the STOP Study, which used risk-based testing. In low HIV prevalence settings, a 
reactive 4th generation HIV Ag/Ab combo screening assay with a negative supplemental 
antibody result is likely a false-positive screening result, but clinicians must still be aware of 
the possibility of acute HIV infection and perform HIV RNA testing to resolve the 
discordant result. We note also that only a small number of patients with possible acute 
retroviral symptoms (4.9%) were tested for acute HIV, and among those screened afterward, 
there was an appreciable rate of new HIV diagnosis (consistent with seroconversion).
Together, the issues of low screening assay predictive value, low acute infection prevalence 
and prolonged time-to-resolution of status are very challenging in an era when there is 
increasing emphasis on immediate initiation of treatment [13, 17, 18]—particularly in 
possible cases of acute HIV infection [19-21]. We found that nearly all (100% at ZSFG, 
99% in STOP) specimens that had S/CO>15 were truly HIV infected. However, S/CO 
ratios<15 were more difficult to interpret, with none of the ZSFG specimens but 60% of 
STOP Study specimens in this range being truly HIV infected. This difference was 
attributable to the large number of acute infections in the STOP Study population, which had 
S/CO ratios in the low range. Thus, S/CO ratios will not distinguish acute from false-
positive specimens. There were also numerous non-acute (MS-positive) infections with 
S/CO rations below 15 in the stop study. Several recent analyses [22-24] have suggested that 
ARCHITECT S/CO ratios in this range likely represent recent HIV infection, such as would 
be expected in a high-risk population like the STOP study. This emphasizes the need for 
rapid nucleic acid-based diagnostics to permit rapid decision making for low S/CO values 
that may be acute or recent infections.
This study reflected early experience with the new algorithm and was limited by the short 
period of observation under the new algorithm (3 months) and by the inability to detect acute 
infections during the study period. This highlights an additional limitation in that because 
we did not test all samples for HIV RNA, we were unable to assess the sensitivity of the new 
algorithm for acute HIV infections in medical settings (as was done in the STOP Study). 
One strength of this study was the ability of the ZSFG PHAST team to do extensive case 
review for every patient that screened HIV-positive during the study period. This allowed us 
to differentiate algorithm performance for patients who were newly diagnosed vs. 
performance for the entire hospital testing population, of which the majority of HIV-positive 
results came from patients who were already known to be infected.
In summary, we have demonstrated that the new HIV algorithm can be implemented in a 
high-throughput medical center laboratory setting without impeding rapid return of results or 
diagnostic test performance. Our experience with the new algorithm suggests that expanding 
testing for acute HIV infection and implementation of rapid viral load diagnostic assays may 
both play a role in improving the effectiveness of HIV testing.
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Highlights
• HIV testing by AR-MS-VL algorithm is feasible and rapid in a large medical 
center.
• Low PPV of the 4th gen. test is due to low prevalence of HIV vs. assay 
specificity.
• 4thgeneration tests with a low S/C ratio may be false-positive or acute HIV 
results.
• Rapid nucleic acid tests are needed to identify and quickly treat acute HIV 
cases.
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Figure 1. Panel A. AR-MS-VL1 Flow at Zuckerberg San Francisco General Hospital (ZSFG), 
Sept – Nov, 2015
1ARCHITECT® HIV Ag/AB Combo (AR) for screening, followed by Multispot HIV-1/
HIV-2 Rapid Test (MS) confirmation, and Abbott RealTime HIV-1 assay (VL) as needed for 
resolution of discrepant results
Panel B. AR-MS-VL1 Flow at STOP Study2, 2010-2013
1ARCHITECT® HIV Ag/AB Combo (AR) for screening, followed by Multispot HIV-1/
HIV-2 Rapid Test (MS) confirmation, and Abbott RealTime HIV-1 assay (VL) as needed for 
resolution of discrepant results
2CDC Screening Targeted Populations to Interrupt On-going Chains of HIV Transmission 
with Enhanced Partner Notification (STOP) Study for targeted testing of MSM; data from 
publicly funded testing sites in San Francisco
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Figure 2. Distribution of signal cut-off ratios for specimens reactive on ARCHITECT screening 
assay at Zuckerberg San Francisco General (ZSFG) (Sept-Nov, 2015) and at the STOP Study1 
(2010-2013)
Distribution of signal cut-off ratio values are shown for specimens classified as false-positive 
or true-positive HIV infections, based on completion of the full AR-MS-VL testing 
algorithm. The dotted horizontal line illustrates the S/CO ratio of 15 previously suggested 
[16] as an upper bound on the distribution of false-positive, AR reactive results. There were 
no acute infections(Multispot indeterminate or Multispot nonreactive specimens that were 
VL positive) in the ZSFG testing population.
1CDC Screening Targeted Populations to Interrupt On-going Chains of HIV Transmission 
with Enhanced Partner Notification (STOP) Study for targeted testing of MSM; data from 
publicly funded testing sites in San Francisco
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